<DOC>
	<DOCNO>NCT02815332</DOCNO>
	<brief_summary>This 12-week , multi-center , double-blind , randomize , three-arm , vehicle-controlled study . Subjects randomize ( 1:1:1 ) 1 % 2 % BPX-01 gel , vehicle . Subjects apply 1g gel thin film entire face least 30 minute bedtime night 12 week . Lesion count , IGA , Patient-Reported Outcomes ( PGI-S PGI-I ) perform assess efficacy . Blood draw collect baseline ( Day 0 ) , Weeks 4 12 evaluate level minocycline plasma . Safety assess vital sign , brief physical examination , clinical laboratory test , cutaneous tolerance score , incidence minocycline-induced skin hyperpigmentation , incidence visual disturbance and/or headache suggestive pseudotumor cerebri , collection adverse event .</brief_summary>
	<brief_title>BPX-01 Minocycline Topical Gel Treatment Acne Vulgaris</brief_title>
	<detailed_description>This phase 2b , randomize , double-blind , vehicle-controlled study Assess Safety Efficacy BPX-01 Minocycline Topical Gel Treatment Moderate Severe Inflammatory Acne Vulgaris . Study Population : Approximately 225 male female subject age 9 40 year moderate severe inflammatory non-nodular acne vulgaris include study . Number Sites : Approximately 15 center United States participate study . Study Duration : Overall study duration expect approximately 24 week ( 6 month ) . The study duration individual subject approximately 16 week ( include screen period ) . Hypothesis : BPX-01 improves disease condition subject moderate severe inflammatory non-nodular acne vulgaris compare vehicle . Objectives : Primary : - To evaluate efficacy BPX-01 minocycline 1 % 2 % topical gel treatment inflammatory non-nodular acne vulgaris Secondary : - To evaluate plasma level minocycline daily application 1 % 2 % BPX 01 topical gel - To evaluate safety BPX-01 minocycline 1 % 2 % topical gel Endpoints : Primary Efficacy Endpoint : - Absolute mean change baseline inflammatory lesion count Week 12 Secondary Efficacy Endpoint : - Proportion subject least two-grade reduction IGA Week 12</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Male female subject age 9 40 year age . 2 . Subjects medical condition , acne vulgaris , opinion investigator , put subject unacceptable risk could interfere study assessment integrity data . 3 . Moderate severe inflammatory nonnodular acne vulgaris . 4 . Female subject childbearing potential ( include prepuberty ) willing use effective contraceptive method least 28 day baseline ( Day 0 ) least 28 day last study product administration sterilize samesex partner duration study . 5 . Treatment hormonal therapy must stable dose frequency least 12 week baseline ( Day 0 ) must remain stable throughout study . 6 . Subjects use makeup , facial moisturizers , cream , lotion , cleanser and/or sunscreen must use product brands/types minimum period 14 day prior baseline ( Day 0 ) , must agree change brand/type frequency use throughout study must agree use makeup , facial moisturizers , cream , lotion , cleanser and/or sunscreens clinic visit day visit . 7 . Subjects must capable give informed consent write informed consent must obtain prior studyrelated procedure . Subject 18 year age must sign assent form , parent ( ) legal representative must read sign informed consent form prior studyrelated procedure . 1 . Female subject breastfeeding , pregnant planning pregnancy study . 2 . Have acne fulminans conglobata , nodulocystic acne . 3 . Have history skin disease , presence skin condition , excessive facial hair , opinion investigator , would interfere study . 4 . Have history cancer lymphoproliferative disease successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma and/or localize carcinoma situ cervix . 5 . Have history minocyclineinduced hepatitis , minocyclineinduced arthritis , minocyclineinduced lupus minocycline/tetracyclineinduced pseudotumor cerebri . 6 . Presence minocyclineinduced hyperpigmentation screen baseline ( Day 0 ) . 7 . Presence visual disturbance and/or headache suggestive pseudotumor cerebri screen baseline ( Day 0 ) . 8 . Have clinical chemistry hematology laboratory value abnormal screen visit consider clinically significant investigator . 9 . Has ALT AST screen great equal 2 time upper limit normal . 10 . Have use face overthecounter ( OTC ) topical medication treatment acne vulgaris include benzoyl peroxide , topical antiinflammatory medication , corticosteroid , salicylic acid , Î±hydroxy/glycolic , antibacterial/antiseptic soap wash within 14 day prior baseline ( Day 0 ) . 11 . Have use prescription topical retinoid ( e.g . tretinoin , tazarotene , adapalene ) antimicrobial ( e.g . clindamycin , erythromycin ) prescription topical medication treatment acne vulgaris within 28 day baseline ( Day 0 ) . 12 . Have use systemic antibiotic systemic antiacne drug mention exclusion criterion within 28 day baseline ( Day 0 ) . 13 . Have use oral , intranasal , injectable corticosteroid within 28 day baseline ( Day 0 ) require study . Inhaled corticosteroid stable medical condition allow . 14 . Have receive investigational therapy ( include investigational drug procedure ) within 28 day baseline ( Day 0 ) plan use one study . 15 . Have facial procedure ( e.g . chemical peel , laser , microdermabrasion ) within 8 week baseline ( Day 0 ) . 16 . Have excessive sun exposure , plan trip sunny climate use tan booth within 28 day prior baseline ( Day 0 ) willing minimize natural artificial sunlight exposure study . 17 . Have receive photodynamic therapy phototherapy blue red light within 12 week baseline ( Day 0 ) . 18 . Have use androgen receptor blocker ( spironolactone flutamide ) within 12 week baseline ( Day 0 ) . 19 . Have use drospirenone , chlormadinone acetate , cyproterone acetate within 26 week baseline ( Day 0 ) . 20 . Have use oral retinoid ( e.g. , isotretinoin ) within 52 week prior baseline ( Day 0 ) vitamin A supplement great 10,000 U/d within 26 week baseline ( Day 0 ) . 21 . History clinically significant drug alcohol abuse last year prior baseline ( Day 0 ) judge investigator . 22 . Has know suspect allergy minocycline , tetracyclineclass antibiotic component investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>